Learning points {#sec1-0300060519847414}
===============

Tofacitinib is efficacious in treating chronic plaque psoriasis, but there may be a higher incidence of adverse reactions.The included studies only compared the efficacy and safety of tofacitinib and placebo, and did not compare these with other drugs that are used to treat chronic plaque psoriasis.

Introduction {#sec2-0300060519847414}
============

Chronic plaque psoriasis is an inflammatory, immune-mediated systemic disease that impacts patients both physically and psychologically, leading to major quality of life impairment.^[@bibr1-0300060519847414]^ The prevalence of psoriasis is about 0.47% in China, but the disease incidence is higher in Europe and North America, at approximately 2%.^[@bibr2-0300060519847414],[@bibr3-0300060519847414]^ Patients with moderate to severe plaque psoriasis usually need phototherapy or systemic agents for treatment.^[@bibr4-0300060519847414],[@bibr5-0300060519847414]^ Prolonged use of classical systemic agents is associated with organ toxicity to the liver, kidney, and mucocutaneous organs, thus limiting their long-term use.^[@bibr6-0300060519847414][@bibr7-0300060519847414][@bibr8-0300060519847414][@bibr9-0300060519847414]--[@bibr10-0300060519847414]^

The Janus kinase (JAK) intracellular signaling pathway has been implicated in the pathogenesis of chronic immune-mediated and inflammatory diseases, including psoriasis.^[@bibr11-0300060519847414]^ The JAK family includes JAK1, JAK2, JAK3, and TYK2. Tofacitinib is an oral JAK inhibitor that mainly interferes with JAK1 and JAK3 signaling. Tofacitinib was approved by the FDA on November 6, 2012 for the treatment of moderate to severe rheumatoid arthritis, and tofacitinib was approved by the Chinese Food and Drug Administration on March 16, 2017 for the treatment of adult patients with moderate to severe active rheumatoid arthritis in whom methotrexate is not effective or who are intolerant to methotrexate treatment. In addition to rheumatoid arthritis, clinical data suggests that tofacitinib has a good effect on the treatment of chronic plaque psoriasis. **However, no relevant studies have evaluated the efficacy of tofacitinib in treating chronic plaque psoriasis.**

Therefore, we conducted a systematic evaluation to analyze and evaluate data from randomized controlled trials (RCTs) on the treatment of chronic plaque psoriasis to provide a reference for its safe and optimal use in the clinic.

Methods {#sec3-0300060519847414}
=======

Eligibility criteria {#sec4-0300060519847414}
--------------------

Only RCTs studying the effects and safety of tofacitinib on patients with chronic plaque psoriasis were included in this study. The co-primary efficacy endpoints were the proportion of patients achieving at least a 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI75 response) from baseline and the proportion of patients achieving a Physician's Global Assessment (PGA) score (on a five-point severity scale where 0 is "clear"; 1 is "almost clear"; 2 is "mild"; 3 is "moderate"; and 4 is "severe") of "clear" or "almost clear" (PGA response). The main secondary endpoints were the proportion of patients achieving at least a 90% reduction in the PASI score (PASI90 response) from baseline. Safety was assessed based on the incidence of adverse events. All studies included were published in English. The protocol was registered with the International Prospective Register of Systematic Reviews (identification number: CRD42017076587).

Search strategy {#sec5-0300060519847414}
---------------

We searched the PubMed, Embase, and Cochrane databases from their earliest dates up to August 2017. The final search string was "tofacitinib" \[Mesh\] OR "tasocitinib" OR "Xeljanz" AND "psoriasis" \[Mesh\] OR "psoriasis" AND randomized controlled trial \[ptyp\]. No additional filters were used. This search resulted in 151 articles ([Figure 1](#fig1-0300060519847414){ref-type="fig"}). No additional articles were found by searching through article references, resulting in the final 151 articles. Using the titles and abstracts of these 151 articles, we eliminated studies that were unrelated to psoriasis, basic science research articles, pilot studies, commentaries, and reviews. This strategy narrowed down the list to 24 articles. The full text of these articles was reviewed to assess their eligibility for inclusion.

![Article identification, assessment, and selection](10.1177_0300060519847414-fig1){#fig1-0300060519847414}

Quality assessment {#sec6-0300060519847414}
------------------

The Cochrane System Evaluator Manual 5.1.0 was used to assess the bias risk of the included RCTs, and the following seven aspects are included: random sequence generation was correct, allocation concealment, blinding status, blinded evaluation results, completeness of information, whether selective reporting was used, and any other risk of bias implementation.

Patient and public involvement {#sec7-0300060519847414}
------------------------------

Patients and the public were not involved in this study.

Data synthesis {#sec8-0300060519847414}
--------------

Descriptive information was collected for each study, including the country of origin, clinical trial number, and diagnostic criteria. Quantitative information included the pooled risk ratio and 95% confidence intervals (CI). The measures of consistency (*I*^2^) for each meta-analysis were described. Subgroup analyses were performed based on the different interventions.

Results {#sec9-0300060519847414}
=======

Study selection and study characteristics {#sec10-0300060519847414}
-----------------------------------------

Studies were selected by two researchers in accordance with the inclusion and exclusion criteria. There were 45 articles initially identified and subjected to literature screening, data extraction, and crosscheck. Any differences were resolved through consultation or by a third researcher. In the case of missing data, the researchers contacted the authors to obtain more information. For literature screening, the titles and abstracts were analyzed first. After excluding reports that were clearly irrelevant, the researchers read the remaining full texts and determined whether the articles met the criteria. This process excluded 18 of the 24 articles, with six articles (seven RCTs) that were available for inclusion (see flow diagram, [Figure 1](#fig1-0300060519847414){ref-type="fig"}). Two researchers extracted data from the seven RCTs (see [Table 1](#table1-0300060519847414){ref-type="table"}).

###### 

Basic characteristics of included studies

![](10.1177_0300060519847414-table1)

  Article                                               Country   Race                         Clinical trial Number   Diagnostic criteria                                                          Male          Mean age (years)                Disease severity         Intervention group                                  Control                                              
  ----------------------------------------------------- --------- ---------------------------- ----------------------- ---------------------------------------------------------------------------- ------------- ------------------------------- ------------------------ --------------------------------------------------- ---------------------------------------------------- -----------------
  Zhang et al. 2017^[@bibr12-0300060519847414]^         China     China, Taiwan, Korea         NCT01815424             PASI score ≥12 and PGA score of "moderate" or "severe" at baseline           65/67/62      40.7±11.3/41.0±12.0/41.7±13.7   moderate to severe       tofacitinib 5 mg twice daily for 16 weeks (n=88)    tofacitinib 10 mg twice daily for 16 weeks (n=90)    placebo (n=88)
  Asahina et al. 2016^[@bibr13-0300060519847414]^       Japan     Japanese                     NCT01519089             PASI score ≥12 or more and PGA score of 3 (moderate) or 4 (severe)           35/36         50.9/46.6                       moderate to severe       tofacitinib 5 mg twice daily for 16 weeks (n=43)    tofacitinib 10 mg twice daily for 16 weeks (n=44)    none
  OPT1-Papp et al. 2015^[@bibr14-0300060519847414]^     Canada    Blacks, whites, Asians       NCT01276639             PASI score ≥12, PGA score of 3 (moderate) or 4 (severe)                      261/261/121   46/46/45                        moderate to severe       tofacitinib 5 mg twice daily for 16 weeks (n=363)   tofacitinib 10 mg twice daily for 16 weeks (n=360)   placebo (n=177)
  OPT2-Papp et al. 2015^[@bibr14-0300060519847414]^     Canada    Black, white, Asian, other   NCT01309737             PASI score ≥12, PGA score of 3 (moderate) or 4 (severe)                      268/257/123   47/44/45                        moderate to severe       tofacitinib 5 mg twice daily for 16 weeks (n=382)   tofacitinib 10 mg twice daily for 16 weeks (n=381)   placebo (n=196)
  Bissonnette et al. 2015^[@bibr15-0300060519847414]^   Canada    White, other                 NCT01186744             PASI score ≥12, PGA score of 3 (moderate) or 4 (severe)                      228/230       45/47                           mild, moderate, severe   tofacitinib 5 mg twice daily for 16 weeks (n=331)   tofacitinib 10 mg twice daily for 16 weeks (n=335)   none
  Bachelez et al. 2015^[@bibr16-0300060519847414]^      France    White, Asian, other          NCT01241591             PASI score ≥12 or more and PGA score of "moderate" or "severe" at baseline   236/238/71    44/44/46                        mild, moderate, severe   tofacitinib 5 mg twice daily for 12 weeks (n=329)   tofacitinib 10 mg twice daily for 12 weeks (n=330)   placebo (n=107)
  Papp et al. 2012^[@bibr17-0300060519847414]^          Canada    Black, white, Asian, other   NCT00678210             PASI score ≥13                                                               29/36         44/43.9                         mild, moderate, severe   tofacitinib 5 mg twice daily for 12 weeks (n=49)    none                                                 placebo (n=50)

PASI, Psoriasis Area and Severity Index; PGA, Physician's Global Assessment

Risk of bias assessment {#sec11-0300060519847414}
-----------------------

There were seven studies that described using the random assignment method and allocation concealment. All seven studies were double-blind, which resulting in a low risk of bias (see [Figure 2](#fig2-0300060519847414){ref-type="fig"}).^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414][@bibr16-0300060519847414]--[@bibr17-0300060519847414]^

![Risk of bias graph](10.1177_0300060519847414-fig2){#fig2-0300060519847414}

Meta-analysis {#sec12-0300060519847414}
-------------

### Efficacy {#sec13-0300060519847414}

We compared the seven RCTs to the different doses of tofacitinib (5 mg or 10 mg twice daily) and to the placebo in adults with chronic plaque psoriasis.^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414][@bibr16-0300060519847414]--[@bibr17-0300060519847414]^ Pooled data from the seven RCTs showed that the tofacitinib 5 mg group had a superior PGA response compared with the placebo group (adjusted RR, 3.77; 95% CI, 3.01--4.71; *I*^2^ = 0%; *P* \< 0.00001) and PASI75 (adjusted RR, 5.31; 95% CI, 4.04--6.97; *I*^2^ = 18%; *P* \< 0.00001). However, the 5 mg dose of tofacitinib appeared to be less effective compared with the 10 mg dose of tofacitinib on the PGA response (adjusted RR, 0.70; 95% CI, 0.63--0.79; *I*^2^= 67%; *P* \< 0.00001) and PASI75 (adjusted RR, 0.68; 95% CI, 0.64--0.73; *I*^2^=35%; *P* \< 0.00001). Four studies reported the PASI90.^[@bibr12-0300060519847414],[@bibr13-0300060519847414],[@bibr16-0300060519847414],[@bibr17-0300060519847414]^ A meta-analysis of those four RCTs showed that the tofacitinib 5 mg group had a greater effect compared with the placebo group on PASI90 (adjusted RR, 14.88; 95% CI, 5.59--39.60; *I*^2^ = 0%; *P* \< 0.00001), but the effect was lower compared with the tofacitinib 10 mg group (adjusted RR, 0.60; 95% CI, 0.49--0.72; *I*^2^ = 0%; *P* \< 0.00001). The differences were statistically significant for these three outcome indicators ([Table 2](#table2-0300060519847414){ref-type="table"}).

###### 

Analysis of efficacy and the association between tofacitinib and placebo

![](10.1177_0300060519847414-table2)

  Outcome or Subgroup                                                                                                                                                                   Studies   Participants   *I*^2^, %   Adjusted risk ratio (95% CI)   *P*
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- -------------- ----------- ------------------------------ -----------
  1.1 PGA response^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414][@bibr16-0300060519847414]--[@bibr17-0300060519847414]^      7         6634                                                      
   1.1.1 tofacitinib 5 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414],[@bibr17-0300060519847414]^                                      5         1829           0           3.77 (3.01, 4.71)              \<0.00001
   1.1.2 tofacitinib 10 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414]^                                                                4         1729           0           5.17 (4.12, 6.48)              \<0.00001
   1.1.3 tofacitinib 5 mg vs. tofacitinib 10 mg^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414]--[@bibr16-0300060519847414]^   6         3076           67          0.70 (0.63, 0.79)              \<0.00001
  1.2 PASI75^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414][@bibr16-0300060519847414]--[@bibr17-0300060519847414]^            7         6634                                                      
   1.2.1 tofacitinib 5 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414],[@bibr17-0300060519847414]^                                      5         1829           18          5.31 (4.04, 6.97)              \<0.00001
   1.2.2 tofacitinib 10 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414]^                                                                4         1729           39          7.30 (5.55, 9.59)              \<0.00001
   1.2.3 tofacitinib 5 mg vs. tofacitinib 10 mg                                                                                                                                         6         3076           35          0.68 (0.64, 0.73)              \<0.00001
  1.3 PASI90^[@bibr12-0300060519847414],[@bibr13-0300060519847414],[@bibr16-0300060519847414],[@bibr17-0300060519847414]^                                                               4         2250                                                      
   1.3.1 tofacitinib 5 mg vs. placebo^[@bibr12-0300060519847414],[@bibr16-0300060519847414],[@bibr17-0300060519847414]^                                                                 3         711            0           14.88 (5.59, 39.60)            \<0.00001
   1.3.2 tofacitinib 10 mg vs. placebo^[@bibr12-0300060519847414],[@bibr16-0300060519847414]^                                                                                           2         615            0           24.57 (8.75, 69.06)            \<0.00001
   1.3.3 tofacitinib 5 mg vs. tofacitinib 10 mg^[@bibr12-0300060519847414],[@bibr13-0300060519847414],[@bibr16-0300060519847414]^                                                       3         924            0           0.60 (0.49, 0.72)              \<0.00001

PASI, Psoriasis Area and Severity Index

### Safety {#sec14-0300060519847414}

The incidence of adverse events (AEs) was higher in the tofacitinib group compared with the placebo group (tofacitinib 5 mg, 54.8% vs. placebo, 50.2%, *P* \< 0.04; tofacitinib 10 mg, 59.5% vs. placebo, 49.3%; *P* \< 0.0001). All studies examined showed that there were no statistical differences in serious AEs (tofacitinib 5 mg, 2.39% vs. placebo, 0.97%; tofacitinib 10 mg, 1.72% vs. placebo, 1.58%), AEs leading to discontinuation (tofacitinib 5 mg, 2.58% vs. 4.23%; tofacitinib 10 mg, 2.84% vs. placebo, 4.22%), or the rate of infection (tofacitinib 5 mg, 10.9% vs. placebo, 10.2%; tofacitinib 10 mg, 12.7% vs. placebo, 9.11%) compared with placebo ([Table 3](#table3-0300060519847414){ref-type="table"}).

###### 

Analysis of safety and the association between tofacitinib and placebo

![](10.1177_0300060519847414-table3)

  Outcome or Subgroup                                                                                                                                                                          Studies   Participants   *I*^2^, %   Adjusted risk ratio (95% CI)   *P*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- -------------- ----------- ------------------------------ ----------
  1.1 Adverse reactions^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414][@bibr16-0300060519847414]--[@bibr17-0300060519847414]^        7         6634                                                      
   1.1.1 tofacitinib 5 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414],[@bibr17-0300060519847414]^                                             5         1829           3           1.10 (1.00, 1.21)              0.04
   1.1.2 tofacitinib 10 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414]^                                                                       4         1729           0           1.21 (1.10, 1.33)              \<0.0001
   1.1.3 tofacitinib 5 mg vs. tofacitinib 10 mg^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414]--[@bibr16-0300060519847414]^          6         3076           12          0.90 (0.85, 0.96)              0.0007
  1.2 Serious adverse events^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414][@bibr16-0300060519847414]--[@bibr17-0300060519847414]^   7         6634                                                      
   1.2.1 tofacitinib 5 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414],[@bibr17-0300060519847414]^                                             5         1829           0           1.51 (0.75, 3.03)              0.25
   1.2.2 tofacitinib 10 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414]^                                                                       4         1729           0           1.01 (0.46, 2.19)              0.99
   1.2.3 tofacitinib 5 mg vs. tofacitinib 10 mg^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414]--[@bibr16-0300060519847414]^          6         3076           34          0.91 (0.60, 1.39)              0.67
  1.3 Discontinuations because of adverse events^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414]--[@bibr16-0300060519847414]^         6         6535                                                      
   1.3.1 tofacitinib 5 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414]^                                                                        4         1730           32          0.65 (0.38, 1.09)              0.10
   1.3.2 tofacitinib 10 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr16-0300060519847414]^                                                                       4         1729           0           0.65 (0.38, 1.10)              0.11
   1.3.3 tofacitinib 5 mg vs. tofacitinib 10 mg^[@bibr12-0300060519847414][@bibr13-0300060519847414][@bibr14-0300060519847414][@bibr15-0300060519847414]--[@bibr16-0300060519847414]^          6         3076           12          0.84 (0.56, 1.26)              0.41
  1.5 Infection^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr15-0300060519847414],[@bibr17-0300060519847414]^                                                                   5         5017                                                      
   1.5.1 tofacitinib 5 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr17-0300060519847414]^                                                                        4         1393           57          0.99 (0.55, 1.79)              0.97
   1.5.2 tofacitinib 10 mg vs. placebo^[@bibr12-0300060519847414],[@bibr14-0300060519847414]^                                                                                                  3         1294           8           1.25 (0.88, 1.77)              0.21
   1.5.3 tofacitinib 5 mg vs. tofacitinib 10 mg^[@bibr12-0300060519847414],[@bibr14-0300060519847414],[@bibr15-0300060519847414]^                                                              4         2330           33          0.79 (0.61, 1.03)              0.08

Discussion {#sec15-0300060519847414}
==========

JAK was identified in the early 1990s^[@bibr18-0300060519847414]^ and is a core member of the protein tyrosine kinase family. The JAK family includes JAK1, JAK2, JAK3, and TYK2. JAK is a receptor-related intracellular protein that plays a key role in cytokine receptor signaling.^[@bibr19-0300060519847414]^ JAK is involved in cell growth, survival, development, and differentiation, and it is also important for immune and hematopoietic functions.^[@bibr20-0300060519847414]^ Tofacitinib is an oral JAK1 and JAK3 inhibitor. Partial inhibition of JAK signaling by tofacitinib leads to a multi-tiered intervention in the cycle of psoriasis pathogenesis, with a direct impact on dysregulated keratinocytes, a reduction in inflammatory infiltrates, and normalization of the interleukin (IL)-23/Th17 axis.^[@bibr21-0300060519847414]^

Seven RCTs involving 3743 patients were included in this study. The meta-analysis showed that tofacitinib 10 mg twice daily was effective in treating chronic plaque psoriasis as measured by PGA responses, PASI75, and PASI90. Although a substantial number of patients who received tofacitinib 5 mg twice daily achieved PGA responses, PASI75, and PASI90, this dose did not meet the statistical criterion for non-inferiority to tofacitinib 10 mg twice daily. However, tofacitinib compared with placebo increased the incidence of adverse reactions, and the incidence of AEs related to tofacitinib 10 mg twice daily was higher compared with tofacitinib 5 mg twice daily.

This study was conducted via a comprehensive search of relevant literature on these topics, and the researchers carefully performed data extraction and rigorously assessed the quality of the included research to reduce bias. Additionally, these RCTs were analyzed by methodology used in evidence-based medicine. Although the selected studies were randomized, had large sample sizes, were multicenter clinical studies, and were high quality, this review has some limitations because of the small number of studies included, which may produce false-positive results. Additionally, the included studies only compared the efficacy and safety of tofacitinib and placebo and did not involve comparisons with other drugs for the treatment of chronic plaque psoriasis. Therefore, the efficacy and safety of tofacitinib in the treatment of chronic plaque psoriasis still requires large and high-quality studies for further confirmation.

Conclusions {#sec16-0300060519847414}
===========

Treatment of chronic plaque psoriasis with tofacitinib is efficacious, but the incidence of adverse reactions is higher with tofacitinib compared with placebo.
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